文献速递胸部肿瘤

完全切除意外N2阳性NSCLC同步放化疗对比化疗的随机II期试验

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-09-28

本研究纳入101例完全切除的意外N2阳性NSCLC患者,随机1:1接受同步放化疗或单纯辅助化疗。同步放化疗组中位无病生存24.7个月,化疗组21.9个月,差异无统计学意义(HR=0.94,95%CI 0.58-1.52,p=0.40);总生存亦无差异(74.3 vs 83.5个月,HR=1.33,95%CI 0.71-2.49)。结论为同步放化疗较铂类化疗 alone 无生存获益。

要点

  • 完全切除意外N2阳性NSCLC中,辅助同步放化疗较单纯化疗未改善无病生存(HR=0.94)。
  • 两组总生存无显著差异(74.3 vs 83.5个月,HR=1.33)。
  • 同步放化疗方案为胸部放疗50 Gy/25次联合每周紫杉醇/顺铂,后续两周期紫杉醇/顺铂。

核心结论

  • 对于完全切除的意外N2阳性NSCLC,辅助同步放化疗较铂类辅助化疗 alone 无生存获益。

研究设计与样本

  • 随机II期试验,纳入101例完全切除的意外N2阳性NSCLC患者,1:1随机分配至同步放化疗组(51例)或化疗组(50例)。
  • 术前分期为N0者74例,N1者27例,两组基线特征均衡。
  • 主要终点为无病生存。

主要发现

  • 同步放化疗组中位无病生存24.7个月 vs 化疗组21.9个月,差异无统计学意义(HR=0.94,95%CI 0.58-1.52,p=0.40)。
  • 同步放化疗组总生存74.3个月 vs 化疗组83.5个月(HR=1.33,95%CI 0.71-2.49),无差异。

关键数值与推荐

  • 同步放化疗组:胸部放疗50 Gy/25次,同步每周紫杉醇50 mg/m2+顺铂25 mg/m2共5周期,后续每3周紫杉醇175 mg/m2+顺铂80 mg/m2共2周期。
  • 化疗组:每3周紫杉醇175 mg/m2+卡铂AUC=5.5共4周期。

临床怎么用

  • 完全切除的意外N2阳性NSCLC患者接受辅助同步放化疗较铂类化疗 alone 未显示生存获益。
  • 辅助化疗后序贯放疗的作用正在评估中,完全切除N2阳性NSCLC的最佳放疗方式需进一步研究。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We investigated whether concurrent chemoradiotherapy (CCRT) would increase survival in patients with completely resected unsuspected N2-positive NSCLC versus in patients who received adjuvant chemotherapy alone. METHODS: Eligible patients were randomly assigned (1:1) to either the CCRT arm or the chemotherapy arm. In the CCRT arm, patients received concurrent thoracic radiotherapy (50 Gy in 25 fractions) with five cycles of weekly paclitaxel (50 mg/m2) and cisplatin (25 mg/m2), followed by two additional cycles of paclitaxel (175 mg/m2) plus cisplatin (80 mg/m2) at 3-week intervals. In the chemotherapy arm, patients received four cycles of adjuvant paclitaxel (175 mg/m2) and carboplatin (area under the curve = 5.5) every 3 weeks. The primary end point was disease-free survival. RESULTS: We enrolled and analyzed 101 patients (51 received CCRT and 50 received chemotherapy). In all, 74 and 27 patients were preoperatively staged as N0 and N1 diseases, respectively. The baseline characteristics were well balanced between the two arms. The median disease-free survival of the CCRT arm was 24.7 months, which was not significantly different from that of the chemotherapy arm (21.9 months) (hazard ratio = 0.94, 95% confident interval: 0.58-1.52, p = 0.40). There was no difference in overall survival (74.3 months in CCRT arm and 83.5 months in the chemotherapy arm) (hazard ratio = 1.33, 95% confident interval: 0.71-2.49). CONCLUSIONS: There was no survival benefit from adjuvant CCRT compared with from platinum-based chemotherapy alone for completely resected unsuspected N2-positive NSCLC. However, the role of sequential radiotherapy administered after adjuvant chemotherapy is being evaluated, and further study is needed to evaluate the optimal radiotherapy approach for completely resected N2-positive NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Sun JM, Noh JM, Oh D, et al. Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28962948. doi:10.1016/j.jtho.2017.09.1954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。